2–4% of high-grade ovarian cancer patients display abnormalities of Anaplastic Lymphoma Kinase (ALK) expression due to either gene copy number gain or to the formation of the ALK fusion gene ALK:FN1; this finding indicates the existence of a potential therapeutic target in a minority of ovarian cancer patients [23]. The gene discussed is ALK; the disease is ovarian carcinoma.